Participating in a self help group cannot replace any of the health services. Neither should it be seen as an alternative form of treatment. We could not agree more with the comment "By no means every patient or relative will benefit from joining a group." For some people help comes from sharing with a friend or taLking to a therapist or counsellor. Furthermore, joining a group comes after a person has recognised his or her handicap or illness. This in itself raises some deep seated questions about identity and may delay the decision to take part in a group. Nevertheless, the existence of self help groups and their recognition by health professionals widen people's choice. Members ofa group find out more about the possible causes of their problem, how to cope with the symptoms, and the range of treatment available. They also have a chance to hear themselves articulate their. problem and gradually begin to come to terms with it. Participating in a self help group can be part of the curing process. This is why we should all support and encourage the existence of self help groups irrespective of whether we are members, relatives, or professionals.
NOREEN MILLER National Self-Help Support Centre, London WC1B 3HU Dose dependent response of symptoms, pituitary, and bone to transdermal. oestrogen in postmenopausal women SIR,-Dr J C Stevenson and his colleagues (17 January, p 181) appear to believe that the relation we have established between plasma oestradiol and its biological actions (22 November, p 1337) is invalid since they hold that the measured responses are "suboptimal." There is no logical or biological basis for this notion: an optimal response may make the measurenment o;f anL effect more certain but its absence does not invalidate the doseresponse curve. Furthermore, we contend that the responses are less "suboptimal" than they believe.
Firstly, although they cite Coope's study as showing that the frequency of flushing does not return to the pretreatment rate until at least two months after oestrogen withdrawal,' they fail to point out that by one month after oestrogen withdrawal the frequency rose to that in the placebo group and indeed after two months was greater than the pretreatment rate. In other studies of transdermal oestradiol the washout period after oestrogen has been four weeks,2 30 days,3 and six weeks,4 and so our period of one month is in line with that of other investigators. In our study only eight of our 26 women had previously received oestrogens; of these, five had stopped a month before the study and the other three had not received oestrogen for 8 weeks, 26. weeks, and 3 years. Thus even using the criteria of Dr Stevenson and his colleagues for oestrogen deficiency the proportion of partially oestrogenised patients was about the same as in Mr Whitehead's own study, in which 25% of the patients had high endogenous oestradiol values. ' Secondly, Mr Whitehead's study is cited to maintain that three weeks is not long enough to assess the effect of transdermal oestradiol.5 Again, this is at variance with the findings of other investigators, all of whom found significant effects of transdermal oestradiol on the frequency ofhot flushes by three2 and four4 weeks.
Indeed, in Coope's study oforal oestrogen replacement the response on switching from placebo to oestrogen was complete by three weeks. ' As for the postmenopausal score, we are grateful for the opportunity to expand on a necessarily abbreviated section of our paper. The symptoms (frequency of hot flushes, vaginal dryness, libido, irritability, depression, and unusual tiredness) were given equal weighting and scored according to severity from 0 (absent) to 4 (severe) by two experienced physicians (MP, PLS). The questionnaire was based on published studies,67 has been used for over a decade in our menopause clinic, and has been accepted in many publications. We have no reason to believe that we are not as capable of performing this clinical assessment as general practitioners and gynaecologists. It is stated but not documented that the responses about symptoms are valid only if one person records the symptom score, and, although we have no data on the variance of the score within and between individuals, wewouldassumethatthevariabilitybetweenobservers would act against us and make a significant difference between basal and treated scores more difficult to demonstrate. The patch size is irrelevant since each patient received only one size of patch and had no idea of its oestrogen content.
The statistical analysis was based on a paired t test between untreated and treated values, as described, and the line drawn was arbitrary, "not arbitrary drawn through the means," which is a solecism. The term "congruent" is used in its literal sense of "agreeing" although there is no reason why it cannot be used in its geometric sense with arbitrary drawn lines. As we expected from the small numbers of patients chosen for each dose group, analysis of variance showed no differences between the dose groups. The object of our study was not to provide definitive dose-response curves, which would require many more patients, but to establish whether transdermal oestradiol reduced gonadotrophin release, bone resorption, and postmenopausal symptoms over the same range of plasma oestradiol concentrations. This it clearly did.
The fact that these three actions become asymptotic at a plasma oestradiol concentration above 150 pmol/l does suggest that plasma concentrations above this are unlikely to confer additional benefits and, because it is generally accepted that adverse effectsaredoserelated,8likelyto cause an increasing incidence ofside effects. Furthermore, because the pituitary (via receptors) and bone (via a mechanism unknown) appear to have similar dose-response and time curves9 10 and because we have previously shown no effect of oestrogen on free calcitriol, parathyroid hormone, and calcitonin over this time period9"' we maintain that the results in this study do support our hypothesis'0'12 that the oestrogen effect on bone resorption is receptor mediated. This action on bone is associated with a resetting of the secretion thresholds of the calcium regulating hormones and not with a change in their plasma concentrations. MUNRO Similar concerns about bias were expressed, specifically that women reporting themselves as non-smokers might actually be active smokers or ex-smokers and that non-smoking women not exposed to smoking at home might still have some exposure away from home. Other possibly more serious biases in the studies conducted were not considered. (These include publishing bias: if an investigator got a weakly or insignificantly negative result for the role ofpassive smoking in lung cancer would he bother submitting it for publication? And if he did, would it be accepted? There seems to be a tendency towards accepting uncritically or less critically manuscripts which are on the right side of the fence on the issue of passive smoking.)
Consideration of the first of these two biases led to a reduction in the estimated relative risk from 1-35 to 1-30 for the paper ofProfessor Wald and his colleagues but from 1 34 to 1-15 in the National Research Council report. This source of bias cannot fully account for the excess over unity ofthe relative risk, albeit the National Research Council report suggests that statistical significance would no longer obtain. And the possibility of other biases is noted.
The two survey studies make differing adjustments for exposure to passive smoking away from home. While Professor Wald and his colleagues make an upward adjustment of 18%, from a relative risk of 1-30 to 1-53, the National Research Council report makes an upward adjustment of only 8%, from 115 to 1-24.
For Autologous blood transfusion SIR,-In the wake of the recent blunder by the BMA it is doubly unfortunate that your leading article on autologous blood transfusion should contain factual errors which could fuel the fears of patients and doctors about transfusion quite unnecessarily.
Dr L A Kay states that non-A non-B hepatitis "often causes chronic active hepatitis or cirrhosis and develops in up to 10% ofblood recipients in the United States." This is misleading, in that it implies that up to 10% of transfusion recipients will develop serious liver disease. Only one study ofthe long term sequelae ofpost-transfusion non-A non-B hepatitis has been reported. Of the 500/o of cases which becamne chronic, as evidenced by raised transaminase activities persisting for more than six months, 10-15% may be expected to show evidence of clinically important liver disease. The National Heart, Lung, and Blood Institute in the USA is so concerned about the lack of clinical data on this subject that it has just issued a request for research proposals to investigate the clinical course of post-transtusion non-A non-B hepatitis.
These figures are almost certainly an overestimate of the problem as they make no allowance for the proportion of recipients who die of their original disease (over 50% in most retrospective studies). Furthermore, the incidence ofpost-transfusion non-A non-B hepatitis is probably much lower in the UK than in the USA, having been found to be 2-4% in coronary bypass patients in the only recent study.2 The true figure may well be even lower as groups at high risk of HIV infection have been excluded from donation.
Selective IgA deficiency occurs in around one in 700 of the population, not 7% as stated by your reviewer. Antibodies to IgA occur in up to 40% of these, but anaphylactic transfusion reactions due to IgE directed against IgA are very uncommon.
I
No one in the blood transfusion service would wish to minimise the risks of transfusion, but it is important that -decisions about alternative, and possibly expensive, strategies are based on accurate information. Autologous blood transfusion is an important option to evaluate, though there is evidence from practical experience elsewhere that it is likely to be applicable only to a small proportion of patients.4 It will have no impact on the care of those patients who make the greatest demands on the transfusion service, such as those with marrow failure or major haemorrhage.
The Scottish National Blood Transfusion Service is currently developing a pilot programme to assess the effectiveness, applicability, and cost of such procedures. Britain. They cite the low incidence of posttransfusion non-A non-B hepatitis after cardiac surgery in a single recent British study.2 Unfortunately, ofthe 248 patients studied onlv 44 were regularly examined for their transaminase activities; the rest were tested only during their stay in hospital and at six months; so long incubation non-A non-B infection, which my be associated with intermittent raised transaminase values,3 would have been missed. The authors themselves remark on their low incidence of non-A non-B hepatitis compared with similar studies in Europe using volunteer blood, which showed an incidence of 18-19%.45 In fact it is no more than the 2-2% rate in hospital patients who have not received a transfusion. 34 If careful prospective studies were done in Britain we should probably find a sharp geographical variation in the incidence of posttransfusion non-A non-B hepatitis, depending on the socioeconomic state of the community, as the incidence varies in the United States of America from 4% to 17%.67
J GILLON D B L MCCLELLAND
Until further long term studies are done we cannot be sure how many patients with non-A non-B hepatitis develop chronic liver disease, but up to 10% is the usually quoted estimate. Drs Gillon and McClelland assert that even this need cause little concern, since half of all transfused patients die of their original disease. My concern is for healthy patients undergoing elective surgery, who are highly unlikely to die before chronic complications of hepatitis infection occur. The number of people at risk because of IgA deficiency is indeed 1 in 700, not 7 in 100, and I apologise for missing the error.
The blood transfusion service developed out of the need to treat battlefield casualties during the second world war, and even today the injured and those with marrow failure must rely on donor blood. But why should those with healthy bone marrows accept any additional risks from blood transfusion when they undergo elective surgery? 
